Institute for Research on Cancer and Aging of Nice, CNRS UMR 7284, INSERM U1081, Centre Antoine Lacassagne, University Cote d'Azur (UCA), 06000 Nice, France.
Biomedical Department, Centre Scientifique de Monaco, 98000 Monaco, Monaco.
Int J Mol Sci. 2020 Jun 29;21(13):4627. doi: 10.3390/ijms21134627.
Neovascular age-related macular degeneration (vAMD), characterized by the neo-vascularization of the retro-foveolar choroid, leads to blindness within few years. This disease depends on angiogenesis mediated by the vascular endothelial growth factor A (VEGF) and to inflammation. The only available treatments consist of monthly intravitreal injections of antibodies directed against VEGF or VEGF/VEGFB/PlGF decoy receptors. Despite their relative efficacy, these drugs only delay progression to blindness and 30% of the patients are insensitive to these treatments. Hence, new therapeutic strategies are urgently needed. Experimental models of vAMD are essential to screen different innovative therapeutics. The currently used in vitro and in vivo models in ophthalmic translational research and their relevance are discussed in this review.
新生血管性年龄相关性黄斑变性（vAMD）的特征是后极部脉络膜新生血管化，可导致在几年内失明。该疾病依赖于血管内皮生长因子 A（VEGF）和炎症介导的血管生成。唯一可用的治疗方法包括每月向玻璃体内注射针对 VEGF 或 VEGF/VEGFB/PlGF 诱饵受体的抗体。尽管这些药物具有相对疗效，但它们仅能延缓失明的进展，而且 30%的患者对这些治疗方法不敏感。因此，迫切需要新的治疗策略。vAMD 的实验模型对于筛选不同的创新疗法至关重要。本文讨论了眼科转化研究中目前使用的体外和体内模型及其相关性。
